C Diff Treatment

C Diff Treatment

1249 bookmarks
Custom sorting
A Young Adult With Multisystem Inflammatory Syndrome Following Weeks of Initial COVID-19 Respiratory Infection, With No Prior COVID-19 Vaccination: A Case Report
A Young Adult With Multisystem Inflammatory Syndrome Following Weeks of Initial COVID-19 Respiratory Infection, With No Prior COVID-19 Vaccination: A Case Report
Multisystem inflammatory syndrome (MIS) following COVID-19, a condition primarily diagnosed in children, has also been observed less frequently in adults. It usually presents with a multitude of symptoms, mimicking a shock-like state characterized by multiple organ failure. Diagnosis often involves ruling out other conditions and timely management to mitigate morbidity and mortality. In this case, a 39-year-old unvaccinated Caucasian male patient reported symptoms of fever, chills, night sweats, diarrhea, headache, nasal congestion, and facial pain. Despite treatment with antipyretics, the fever persisted. The patient had tested positive for COVID-19 via polymerase chain reaction (PCR) six weeks prior. Clinical findings included low oxygen saturation, sinus tachycardia, abnormal liver function, elevated inflammatory markers, a negative respiratory viral panel, a negative immunologic workup, and a positive Clostridium difficile (C. difficile) PCR. Following complaints of chest pain which quickly escalated to cardiac arrest, he was diagnosed with myopericarditis. These manifestations met the multisystem inflammatory syndrome in adults (MIS-A) diagnostic criteria as stipulated by the Centers for Disease Control and Prevention. The diagnosis of MIS-A was reached through exclusion. Notably, the patient responded well to symptomatic management. Given the infrequent occurrence of MIS-A cases, even in 2023, it remains a challenging diagnosis. Despite existing guidelines for management, the recovery of this patient solely through symptomatic treatment prior to the consideration of conventional treatment is striking. The patient had concurrent infections, including a C. difficile infection, but these did not account for the overall clinical presentation, particularly the myopericarditis and positive laboratory findings.
·cureus.com·
A Young Adult With Multisystem Inflammatory Syndrome Following Weeks of Initial COVID-19 Respiratory Infection, With No Prior COVID-19 Vaccination: A Case Report
A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity - PubMed
A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity - PubMed
Our findings suggest that metronidazole and vancomycin are equally effective for the treatment of mild CDAD, but vancomycin is superior for treating patients with severe CDAD.
·pubmed.ncbi.nlm.nih.gov·
A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity - PubMed
Management of Clostridoides Difficile: A Focus on the Pharmacist's Role in the Care Continuum
Management of Clostridoides Difficile: A Focus on the Pharmacist's Role in the Care Continuum
Patient education and counseling play a critical role in preventing C. difficile recurrence, and pharmacists are uniquely positioned to provide treatment recommendations, educate patients and health care providers, optimize transitions of care, and reduce the risk of recurrent CDI.
·pharmacytimes.com·
Management of Clostridoides Difficile: A Focus on the Pharmacist's Role in the Care Continuum
Allison Jolley, PharmD. on Twitter
Allison Jolley, PharmD. on Twitter
“RT @pharmso_hard: 🎙️ New Episode Alert! Tune in to our latest episode, "In Patient Management of Clostridium difficile" with Alaina DeKerle…”
·twitter.com·
Allison Jolley, PharmD. on Twitter
Late poor outcomes of Clostridioides difficile infections in oncological patients: A multicentre cohort study - PubMed
Late poor outcomes of Clostridioides difficile infections in oncological patients: A multicentre cohort study - PubMed
Oncological patients presented a higher risk of poor outcomes after CDI. Their early and late mortality rates were higher than in the general population, and in parallel, those undergoing chemotherapy (especially those receiving metronidazole) had higher rates of recurrence.
·pubmed.ncbi.nlm.nih.gov·
Late poor outcomes of Clostridioides difficile infections in oncological patients: A multicentre cohort study - PubMed
Treatment issues in recurrent Clostridioides difficile infections and the possible role of germinants - PubMed
Treatment issues in recurrent Clostridioides difficile infections and the possible role of germinants - PubMed
Clostridioides difficile is the number one cause of hospital-acquired infections in the United States and one of the CDC's urgent-level pathogen threats. The inflammation caused by pathogenic C. difficile results in diarrhea and pseudomembranous colitis. Patients who undergo clinically …
·pubmed.ncbi.nlm.nih.gov·
Treatment issues in recurrent Clostridioides difficile infections and the possible role of germinants - PubMed
Gut microbiota changes associated with Clostridioides difficile infection and its various treatment strategies - PubMed
Gut microbiota changes associated with Clostridioides difficile infection and its various treatment strategies - PubMed
Human gut microbiota are critical to both the development of and recovery from Clostridioides difficile infection (CDI). Antibiotics are the mainstay of CDI treatment, yet inherently cause further imbalances in the gut microbiota, termed dysbiosis, complicating recovery. A variety of microbio …
·pubmed.ncbi.nlm.nih.gov·
Gut microbiota changes associated with Clostridioides difficile infection and its various treatment strategies - PubMed
Use of Live-JSLM in the Treatment of CDI
Use of Live-JSLM in the Treatment of CDI
Joseph Reilly, BS, PharmD, BCGP, provides an overview of a new FDA-approved FMT therapy, live-jslm for the treatment of CDI.
·news.google.com·
Use of Live-JSLM in the Treatment of CDI
Advances in the CDI Treatment Landscape
Advances in the CDI Treatment Landscape
Experts discuss new and emerging treatments the management of CDI, highlighting the phase 3 trials for SER 109.
·news.google.com·
Advances in the CDI Treatment Landscape
Microbiome Science on Twitter
Microbiome Science on Twitter
Don't miss the @SIDPharm Live CE Webinar on the topic: Microbiome Restoration: "What Therapies Can I Use for My "Gut Check"? #microbiome #Cdiff #CDI For additional details and to register, please click here: https://t.co/bEHc2UI7ZW pic.twitter.com/MLZEdVttNp— Microbiome Science (@MbiomeScience) June 7, 2023
·twitter.com·
Microbiome Science on Twitter
Building a C Diff Community and Advocating for Survivors and Caregivers
Building a C Diff Community and Advocating for Survivors and Caregivers
The Peggy Lillis Foundation (PLF) for C diff Education & Advocacy has been working to help people affected by the healthcare associated infection and getting involved with public advocacy including their support of the prospective antibiotic-related law, the Pasteur Act.
·contagionlive.com·
Building a C Diff Community and Advocating for Survivors and Caregivers
Clostridium difficile in inflammatory bowel disease - PubMed
Clostridium difficile in inflammatory bowel disease - PubMed
Clinicians must remain vigilant in the prompt diagnosis and treatment of CDI in IBD patients. Corticosteroids, unnecessary antibiotics, and ongoing colonic inflammatory disease are modifiable risk factors. Improved infection control measures, newer IBD medications, and using effective CDI treatments …
·pubmed.ncbi.nlm.nih.gov·
Clostridium difficile in inflammatory bowel disease - PubMed
Microbiome Science on Twitter
Microbiome Science on Twitter
#Cdiff infection can lead to extended hospital stays ⬆️ #GITwitter #IDTwitter #gutheath #MicrobiomeMonday pic.twitter.com/5wpJ355kOz— Microbiome Science (@MbiomeScience) May 29, 2023
·twitter.com·
Microbiome Science on Twitter
Evaluating antimicrobial duration for Gram-negative bacteremia in patients with neutropenia due to hematologic malignancy or hematopoietic stem cell transplantation - PubMed
Evaluating antimicrobial duration for Gram-negative bacteremia in patients with neutropenia due to hematologic malignancy or hematopoietic stem cell transplantation - PubMed
Our data suggest that short antimicrobial courses had comparable 90-day outcomes as intermediate and prolonged regimens for GN-BSI among immunocompromised patients with neutropenia.
·pubmed.ncbi.nlm.nih.gov·
Evaluating antimicrobial duration for Gram-negative bacteremia in patients with neutropenia due to hematologic malignancy or hematopoietic stem cell transplantation - PubMed
Clostridium difficile in inflammatory bowel disease - PubMed
Clostridium difficile in inflammatory bowel disease - PubMed
Clinicians must remain vigilant in the prompt diagnosis and treatment of CDI in IBD patients. Corticosteroids, unnecessary antibiotics, and ongoing colonic inflammatory disease are modifiable risk factors. Improved infection control measures, newer IBD medications, and using effective CDI treatments …
·pubmed.ncbi.nlm.nih.gov·
Clostridium difficile in inflammatory bowel disease - PubMed
Challenges in the Management of CDI
Challenges in the Management of CDI
Andrew Skinner, MD, reviews challenges in managing CDI, as well as the treatment guidelines from IDSA, SHEA, and ACG.
·news.google.com·
Challenges in the Management of CDI